Methods for increasing endogenous levels of corticotropin-releasing factor
CA 2244864 A1 · Owner: University Of Reading · Inventors: Desouza, Errol B.; Lowry, Phillip J.; Sutton, Steven W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Levels of free corticotropin-releasing factor (CRF) or CRF-related peptide are increased by administration to a patient of a ligand inhibitor of a CRF/CRFbinding protein complex or CRF-related peptide/CRF-binding protein complex. The ligand inhibitor binds to CRF-binding protein thereby causing the release , of CRF or increasing the level of the CRF-related peptide. The ligand inhibitor may be a peptide derived from CRF or a related protein or a nonpeptide. Administration of the ligand inhibitor may provide improvement in learning and memory, in decreasing food intake or in providing treatment for diseases associated with low levels of CRF in the brain notably Alzheimer's , disease. A …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 29, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 29, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 29, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.